Nuplazid, a promising yet unapproved drug for Parkinson's disease has been granted Priority Review status by the Federal Food & Drug Administration (FDA) in November 2015. The FDA's Priority Review designation is significant as a decision by the FDA will now be granted by May 1, 2016; priority review designation fast tracks a drug's approval process through the FDA for drugs. Nuplazid And Parkinson's PDP If approved, Nuplazid would be the first FDA approved drug to treat … [Read more...] about Nuplazid Update For Parkinson’s Drug